πρόβλημα με γραμματοσειρά σέ pdf

Ιστοσελίδα · από **Th P** » 24 Νοέμ 2010, 21:12

Καλησπέρα στήν κοινότητα

Γνωρίζει κάποιος κάτι γι`αυτή τή γραμματοσειρά?
μέ το acrobat υπάρχει πρόβλημα σέ συγκεκριμένα σημεία
όπως αυτό πού φαίνεται δίπλα στόν τίτλο τού άρθρου, όπου κανονικά βρίσκονται οι συγγραφείς.

Μέ τήν εφαρμογή προβολής εγγράφων τά πράγματα είναι ακόμα χειρότερα, το πρόβλημα αφορά ολόκληρο το άρθρο.

στο google δέν δρήκα κάτι γιά

Κώδικας: Επιλογή όλων: IODIOB+AdvFrutiger-L

από **pros** » 24 Νοέμ 2010, 23:25

http://www.fonts.com/FindFonts/detail.h ... tid=191443

http://forums.adobe.com/thread/393000

Φαίνεται ότι είναι αρκετά συχνό το πρόβλημα και δεν αφορά την συγκεκριμένη γραμματοσειρά.
Δοκίμασε κάποια άλλη εφαρμογή ανάγνωσης εγγράφων.
Θα σου συνιστούσα το Okular.

Υπάρχει ακόμη μία δυνατότητα...

Από το τερματικό, μπορείς να χρησιμοποιήσεις το pdftohtml,
για να μετατρέψεις το pdf σε html και να το ανοίξεις με τον περιηγητή...

Spoiler: show

Ιστοσελίδα · από **Th P** » 25 Νοέμ 2010, 10:15

Καλημέρα στήν κοινότητα

@pros ευχαριστώ γιά τήν απάντηση
προσωρινά το πρόβλημα λύνεται κάνοντας copy-paste τίς προβληματικές περιοχές από το acrobat reader στόν επεξεργαστή κειμένου τού Ο.Ο.

όσον αφορά το okular δέν τό έβαλα λόγω εξαρτήσεων με kde,
μετά τήν ζημιά πού έπαθα πρίν λίγες μέρες αποφεύγω νά βάζω επιπλέον προγράμματα πού χρειάζονται κατά οποιονδήποτε τρόπο `ξένες` εξαρτήσεις.
Όποιος καεί στόν χυλό, φυσάει και τό γιαούρτι!

Ανέβασα τό άρθρο εδώ: http://hotfile.com/dl/84815842/5517484/Eye_10_DuoTrav_vs_Xalacom_24-hr_XFG.pdf.html
ώστε άν θέλει κάποιος πού έχει το okular νά το κατεβάσει και να μάς διαφωτίσει

Ευχαριστώ καί πάλι
Θανάσης Π.
Update: χρησιμοποιώντας το pdftohtml, στόν περιηηγητή εμφανίζεται ακριβώς όπως καί στόν acrobat reader

Ιστοσελίδα · από **Th P** » 03 Δεκ 2010, 01:12

Ούτε το okular το διαβάζει
το αποτέλεσμα είναι ίδιο μ`αυτό τής εφαρμογής προβολής εγγράφων

από **pros** » 03 Δεκ 2010, 01:24

Το σκεφτόμουν, κάποια στιγμή και ξέχασα να το δημοσιεύσω...

Αφού μετατρέψεις το pdf σε html, άνοιξε το με το gedit,
και ψάξε το σημείο που έχει πρόβλημα και με το acrobat,
μήπως δεις κάτι που σου δώσει καμιά ιδέα...

Ιστοσελίδα · από **Th P** » 03 Δεκ 2010, 01:28

Θά το δοκιμάσω κι`αυτό

Ευχαριστώ καί πάλι

Ιστοσελίδα · από **Th P** » 03 Δεκ 2010, 15:30

Kαλημέρα στήν κοινότητα

στήν μετατροπή μέ το pdftohtml, παράγονται 3 αρχεία
στό άνοιγμά τους με gedit:
1.

καί μέ επιλογή Δυτική ΙSO 8859

Κώδικας: Επιλογή όλων: <!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN"><HTML> <HEAD> <TITLE></TITLE> </HEAD> <BODY> <A name=1></a>Eye (2010), 1â8 & 2010 Macmillan Publishers Limited All rights reserved 0950-222X/10 $32.00 <a href="http://www.nature.com/eye">www.nature.com/eye</a> 24-h Intraocular AGP Konstas1, DG Mikropoulos1, TA Embeslidis1, CLINICAL AT Dimopoulos1, A Papanastasiou1, A-B Haidich2 pressure control and WC Stewart3 with evening-dosed travoprost/timolol, STUDY compared with latanoprost/timolol, ï¬xed combinations in exfoliative glaucoma Abstract Keywords: 24-h intraocular pressure; efï¬cacy; travoprost/timolol ï¬xed combination; Purpose To evaluate 24-h efï¬cacy of latanoprost/timolol ï¬xed combination; travoprost/timolol ï¬xed combination (TTFC) exfoliative glaucoma vs latanoprost/timolol ï¬xed combination (LTFC) in exfoliative glaucoma (XFG). Design A prospective, single-masked, crossover, active-controlled, randomized Introduction 24-h comparison. 1Glaucoma Unit, Methods After up to a 6-week medicine-free Recently, the travoprost/timolol maleate ï¬xed Department of period, XFG patients were randomized to either combination (DuoTrav, Alcon Laboratories, Inc., Ophthalmology, First TTFC or LTFC for 3 months, dosed each Fort Worth, TX, USA) gained commercial University, Thessaloniki, evening, and then changed to the opposite approval in Europe. Barnebey et al<a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">1 </a>showed in a Greece treatment for another 3 months. At the end of regulatory trial that morning-dosed travoprost/ 2Department of Hygiene, the washout, and both treatment periods, a 24-h timolol ï¬xed combination (TTFC) provided a Aristotle University of intraocular pressure (IOP) curve was measured. further reduction of intraocular pressure (IOP) Thessaloniki, Thessaloniki, Results In total, 40 patients completed the of 0.9â2.4 mm Hg compared with evening-dosed Greece study. The TTFC group showed a lower travoprost. mean absolute 24-h IOP (18.7Â±2.6 vs In contrast, the latanoprost/timolol maleate 3Department of 19.6Â±2.6 mm Hg, Po0.001), maximum IOP ï¬xed combination (Xalacom, Pï¬zer, Inc., New Ophthalmology, PRN Pharmaceutical Research (20.5Â±2.6 vs 21.5Â±2.6 mm Hg, Po0.001) and York City, NY, USA), the ï¬rst prostaglandin/ Network, LLC, Charleston, 24-h IOP range (3.4Â±1.3 vs 4.1Â±1.6 mm Hg, timolol ï¬xed combination available, showed SC, USA P ÂŒ 0.01). At individual time points, TTFC a 1.1â1.2 mm Hg difference between this showed reduced IOPs compared with LTFC, preparation, dosed in the morning, to evening- Correspondence: after a Bonferroni correction, at 1000, 1800, dosed latanoprost.<a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">2,3 </a>Therefore, it is possible WC Stewart, Department of and 2200 hours (Pp0.04). No statistical that the travoprost-based ï¬xed combination Ophthalmology, PRN Pharmaceutical Research differences existed at hours: 0600, 1400, and might have a slight efï¬cacy advantage over the Network, LLC, 6296 Rivers 0200 (PX0.05) and for the minimum IOP latanoprost-based product. Recent data by Avenue, Suite 309, (P ÂŒ 0.09). Topouzis et al<a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">4 </a>showed little difference in a Charleston, SC 29406, USA Conclusions This study suggests that direct comparison between both these ï¬xed Tel: ÃŸ 843-762-6500; evening-dosed TTFC may provide greater 24-h combinations, when both were dosed in the Fax: ÃŸ 843-762-7444. E-mail: <a href="mailto:info@prnorb.com">info@prnorb.com</a> IOP reduction, primarily at the 1800 hours morning, over a three-point diurnal curve. time point, compared with LTFC in XFG. Nonetheless, previous data by Konstas et <a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">al5â7</a> Received: 26 March 2010 Eye advance online publication, 23 July 2010; evaluating the latanoprost/timolol and TTFCs, Accepted in revised form: <a href="http://dx.doi.org/10.1038/eye.2010.100">doi:10.1038/eye.2010.100</a> have shown that evening dosing provides better 7 June 2010 <hr> <A name=2></a>24-h IOP control AGP Konstas et al 2 24-h IOP control compared with the respective iris colour or eyelash changes; risk for uveitis or cystoid individual prostaglandin component. Therefore, evening macular oedema in this trial; or history of ocular herpes dosing might better separate any potential efï¬cacy simplex, reactive airway disease, second- or third-degree differences between the latanoprost and travoprost- heart block, poorly compensated congestive heart failure based ï¬xed combinations. or concomitant use of systemic b-blockers. The purpose of this study was to evaluate the 24-h IOP efï¬cacy between evening-dosed TTFC and latanoprost/ Methods timolol ï¬xed combinations (LTFCs) in exfoliative glaucoma (XFG) patients. All patients signed an informed consent agreement approved by an institutional review board (Bioethics Committee of the Medical School, Aristotle University Materials and methods of Thessaloniki, Thessaloniki, Greece) before any procedures were performed. The Treaty of Helsinki Patients was followed for this study. At visit 1, subjects had an Patients were recruited for this prospective, single- ophthalmic and systemic history taken and had dilated masked, crossover study from the Glaucoma Unit of the funduscopy, gonioscopy, and automated full threshold First University Department of Ophthalmology, AHEPA perimetry performed (Humphrey 24â2 test, SITA Hospital, Thessaloniki, Greece (Clinical Trial Number: standard). At this visit, as well as at all other visits, NCT00757835). We included patients of either gender, the IOP (two measurements at 1000 hoursÂ±1 h were older than 39 years of age, who had a clinical diagnosis of averaged) was measured and Snellen visual acuity XFG in at least one eye (study eye) and, at baseline, an and slit lamp biomicroscopy were performed. This untreated IOP of 425 mm Hg at 1000 hours (Â±1 h). The time was chosen as the peak pressure in Greece based clinical diagnosis of XFG relied on the clinical detection on previous <a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">data.9,10 </a>Qualiï¬ed XFG patients were then of exfoliation material visible on the anterior lens surface washed out of their glaucoma medications in both in a typical conï¬guration and open, anterior chamber eyes and asked to return in 6 weeks for patients on angles on indentation gonioscopy.<a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">8 </a>All study patients previous prostaglandin therapy, and 4 weeks for had early-to-moderate XFG (for this study this was those on previous b-blocker therapy, for the baseline deï¬ned as glaucomatous disc damage with disc cupping visit (visit 2). not exceeding 0.8 and reproducible glaucomatous visual At visit 2, and at all other 24-h monitoring visits (visits ï¬eld loss o14.0 dB in the study eye with Humphrey 4 and 6), patients had sitting IOP measurements at 0600, 24â2 automated perimetry). 1000, 1400, 1800, 2200, and 0200 hours. Patients who met We excluded XFG patients who received therapy if the IOP entry requirements were randomly assigned, by they had a previous history of unresponsiveness a computer generated randomized number list, to receive (deemed to be a morning IOP reduction of o10%) to any either the TTFC or LTFC for the ï¬rst 3-month treatment anti-glaucoma medication, including LTFC or timolol, or period (Â±2 weeks) to be instilled one drop to the study there was a history of non-adherence. Patients were also eye at 2000 hours. No washout period was used between excluded if they showed: unreliable applanation groups. The study was designed to accomplish the tonometry; inadequate visualization of the ocular washout of the period 1 medicine over the 3-month fundus or anterior chamber; a concurrent infectious/ treatment of period 2.<a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">11</a> noninfectious conjunctivitis, keratitis, or uveitis; a history A safety evaluation was performed after 2 weeks of of hypersensitivity to any components of the treatment (visit 3). At the end of period 1, a 24-h curve preparations used in this trial; woman of child-bearing was again performed (visit 4). Patients were then potential or not using reliable birth control; pregnancy or switched to the second study medicine for period 2. lactation; a clinically severe medical or psychiatric A safety visit was again performed after 2 weeks of condition; participation (or current participation) in any treatment (visit 5) and a ï¬nal 24-h curve was performed investigational drug or device trial within the previous 3 at the end of the second 3-month (Â±2 weeks) treatment months before the screening visit; an intraocular period (visit 6). conventional surgery or laser surgery in the participating The same investigators at the clinical site measured the eye; risk of visual ï¬eld or visual acuity worsening as a IOP and used the same calibrated instrument (Goldmann consequence of participation in the trial; an inability to Applanation Tonometer, Haag-Streit, Koeniz, give informed consent; anticipated change in systemic Switzerland) to perform the 24-h monitoring of the IOP. hypotensive therapy during the active treatment portion During the study, the investigators, staff, and patients of the trial; progressive retinal or optic nerve disease were masked to the treatment regimen. A dosing apart from glaucoma; unwillingness to accept the risk of coordinator allocated the medications to the patients Eye <hr> <A name=3></a>24-h IOP control AGP Konstas et al 3 according to a code and did not participate in this trial in TTFC than on latanoprost/timolol maleate ï¬xed any other way. This was a single-masked study. The combination using unpaired t-test for quantitative commercially available medicine bottles were masked by variables and w2 test or Fisherâs exact test, when the placing a label over the medicine bottle. Patients were expected cell count was o5, for qualitative variables. A instructed not to show the labeled medicine bottle to the correlation coefï¬cient was used to analyze the reduction staff or investigators. The medicine was single masked in the IOP.<a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">12 </a>Adverse events were evaluated by a because of the cost in time and in money to arrange for McNemarâs test, a paired w2 test, because of the crossover sterile transfer of both treatments to similar unmarked design of the study<a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">.17 </a>Analyses were conducted using bottles. The staff was masked to the study medicine SPSS 15.0 (SPSS, Inc., Chicago, IL, USA). except a dosing coordinator. Patients were admitted to the hospital in the morning and measurements were recorded at 1000, 1400, 1800, Results 2200, 0200, and 0600 hours. At the 2200 hours Patients measurement, patients were awake at bed rest. The 0200 and 0600 hours IOP measurements were performed Patient characteristics of those included in this study are immediately after wakening and at the slit lamp. Patients shown in <a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#4">Table 1. </a>In all, 40 phakic patients completed the were encouraged to carry out a normal life as much as study of 44 enrolled. Four patients were discontinued possible within the hospital boundaries. from study medicine before the completion of both Patients were instructed regarding correct medication 24-h IOP curves; for either adverse events (two in the instillation and adherence. In this study, all patients were travoprost/timolol period, one in the latanoprost/ instructed to perform nasolacrimal occlusion for 1 min timolol period), and one patient was lost to follow-up. after instillation of each study eye drop. At each visit, In total, 22 were randomized to TTFC and 18 to LTFC local and systemic side effects that occurred during the treatment in period 1. The baseline characteristics of treatment period were recorded. Side effects were the treatment groups were similar except for the age evaluated by asking patients a general query regarding (P ÂŒ 0.002) and the visual acuity (P ÂŒ 0.04). their state of health. Patients also were asked their compliance to the study medicine using a general query. Intraocular pressure The mean IOP and the pressure reductions from baseline Statistics are shown in <a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#4">Tables 2 and 3, </a>as well as <a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#5">Figure 1. </a>The IOP Statistical analyses compared the primary efï¬cacy was signiï¬cantly reduced from untreated baseline at variable, mean 24-h IOP curve (the average pressure for each individual time point and for the mean 24-h the six time points evaluated), using a repeated measures pressure for both treatment groups (Po0.001). When of analysis. Individual time points were evaluated with a treatments were compared directly, for the primary paired t-test within the analysis of variance (ANOVA), in efï¬cacy variable, the 24-h average pressure, the TTFC case of signiï¬cant treatment and time effe<a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">ct.12 </a>A modiï¬ed showed a lower absolute IOP levels for the 24-h curve Bonferroni-correction was used to adjust P-values for (Po0.001, <a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#4">Table 2). </a>The difference between the two multiple comparisons in all individual time points medicines was 0.9Â±1.2 mm Hg. This was true also for the using a range of corrections from a/1â6 depending on maximum pressure (20.5Â±2.6 vs 21.5Â±2.6 mm Hg, the respective P-value <a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">rank.13 </a>The signiï¬cance level Po0.001) and for the 24-h range of pressure (3.4Â±1.3 vs was set at 5% and a two-way analysis was used for all 4.1Â±1.6 mm Hg, P ÂŒ 0.01). other tests. There was a signiï¬cant treatment effect (Po0.001) and As calculated from the PS programme, this 24-h study time effect (P ÂŒ 0.01) within the ANOVA, therefore the had an 80% power to identify a 1.25 mm Hg difference treatments were compared at individual time points in between individual time points and between mean 24-h these post hoc analyses. There was also a signiï¬cant period pressures assuming a SD of 2.8 mm Hg between effect (P ÂŒ 0.02) with both medicines showing a slightly treatments<a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">.14â16 </a>In those patients that both eyes qualiï¬ed, lower pressure at the end of period 2 compared with only one eye was randomly selected for analysis. period 1. However, there was no carry over effect so the The secondary primary efï¬cacy variables for pressure, treatment order did not affect the IOP results (P ÂŒ 0.74). the mean 24-h range (average of the highest time point At individual time points, the TTFC reduced the IOP minus the lowest time point for each individual patient) better than the LTFC, after a modiï¬ed Bonferroni as well as the mean maximum and minimum pressures correction, at 1000, 1800, and 2200 hours (Pp0.04). In were analyzed by a paired t-test. In addition, baseline contrast, no statistical differences existed at hours: 06 00, characteristics were compared in patients ï¬rst started on 1400, and 0200 (PX0.05) and for the minimum pressure Eye <hr> <A name=4></a>24-h IOP control AGP Konstas et al 4 Table 1 Overall baseline characteristics and comparison between treatments Characteristic Baseline N ÂŒ 40 TTFC N ÂŒ 22a LTFC N ÂŒ 18a P-value Male 19 (47) 11 (50) 10 (56) 0.76 Female 21 (53) 11 (50) 8 (44) Mean age (years) 68.2Â±8.4 64.7Â±8.8 72.6Â±6.0 0.002 Mean morning baseline intraocular pressure (mm Hg) 31.3Â±2.8 29.9Â±2.4 30.3Â±3.3 0.64 Mean Snellen best-corrected visual acuity 0.8Â±0.2 0.9Â±0.2 0.7Â±0.3 0.04 Mean vertical cup/disc ratio 0.6Â±0.1 0.6Â±0.1 0.6Â±0.1 0.80 Mean visual ï¬eld loss mean deviation (dB) Ã7.5Â±3.3 Ã7.7Â±3.4 Ã7.4Â±4.4 0.85 Mean corneal thickness 539Â±27 534Â±26 545Â±27 0.22 Most common previous therapies 0.44 Dorzolamide/timolol ï¬xed combination 11 (27) 6 (27.3) 5 (27.8) TTFC 5 (12) 4 (18.2) 1 (5.6) Bimatoprost/timolol ï¬xed combination 4 (10) 2 (9.1) 2 (11.1) Travoprost 4 (10) 3 (13.6) 1 (5.6) LTFC 3 (7) 0 (0) 3 (16.7) Dorzolamide/timolol ï¬xed combination ÃŸ travoprost 3 (7) 1 (4.5) 2 (11.1) Other 10 (25) 6 (27.3) 4 (22.2) Abbreviations: LTFC, latanoprost/timolol ï¬xed combination; TTFC, travoprost/timolol ï¬xed combination. Data are shown as meanÂ±SD, or as number of patients (%). aThese two columns represent ï¬rst period treatment characteristics before changing to the opposite treatment. Table 2 Absolute intraocular pressure levels (P-values are adjusted for the Bonferroni correction so any value o0.05 is statistically signiï¬cant) Baseline TTFC LTFC Mean difference P-valuea Mean 24-h 28.5Â±2.6 18.7Â±2.6 19.6Â±2.6 Ã0.9Â±1.2 o0.001 0600 hours 29.7Â±3.5 19.1Â±2.6 19.7Â±2.3 Ã0.6Â±1.5 0.06 1000 hours 30.4Â±3.5 18.3Â±2.3 19.2Â±2.3 Ã0.8Â±1.8 0.04 1400 hours 28.7Â±2.9 18.7Â±2.6 19.6Â±2.9 Ã0.9Â±2.4 0.05 1800 hours 28.7Â±3.2 18.6Â±2.6 20.3Â±2.9 Ã1.7Â±2.6 o0.001b 2200 hours 27.1Â±2.9 18.6Â±3.2 19.3Â±3.2 Ã0.7Â±1.8 0.04 0200 hours 26.6Â±4.5 18.8Â±3.2 19.4Â±3.9 Ã0.6Â±1.8 0.05 Maximum 31.9Â±3.2 20.5Â±2.6 21.5Â±2.6 Ã1.1Â±1.5 o0.001 Minimum 25.3Â±2.6 17.0Â±2.3 17.5Â±2.6 Ã0.4Â±1.6 0.09 24-h range 6.6Â±2.6 3.4Â±1.3 4.1Â±1.6 Ã0.6Â±1.5 0.01 Abbreviations: LTFC, latanoprost/timolol ï¬xed combination; TTFC, travoprost/timolol ï¬xed combination. aBetween treatments. bBonferroni adjusted P-values. Data are shown as meanÂ±SD (mm Hg). Table 3 Intraocular pressure reduction from baseline Further, there was no correlation of IOP to corneal thickness for TTFC (r ÂŒ 0.17, P ÂŒ 0.31) or LTFC treatment TTFC LTFC Mean difference P-valuea group (r ÂŒ 0.23, P ÂŒ 0.15). The baseline and mean corneal Mean 24-h 9.8Â±2.3 8.9Â±1.9 Ã0.9Â±1.2 o0.001 thickness measurements are shown in <a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#4">Table 1.</a> 0600 hours 10.6Â±2.6 10.0Â±2.9 Ã0.6Â±1.5 0.06 1000 hours 12.1Â±3.5 11.2Â±3.2 Ã0.8Â±1.8 0.04 1400 hours 10.1Â±3.2 9.1Â±2.6 Ã0.9Â±2.4 0.05 1800 hours 10.0Â±3.2 8.3Â±2.9 Ã1.7Â±2.6 o0.001b Adverse events 2200 hours 8.6Â±3.2 7.9Â±3.2 Ã0.7Â±1.8 0.04 0200 hours 7.8Â±3.5 7.2Â±3.5 0.6Â±1.8 0.05 There was no statistical difference between the two treatment groups for any adverse event <a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#6">(Table 4). </a>The Abbreviations:LTFC, latanoprost/timolol ï¬xed combination; TTFC, travoprost/timolol ï¬xed combination. most common adverse event detected was conjunctival aBetween treatments. hyperaemia, which was found in 10% (n ÂŒ 4) of patients bBonferroni adjusted P-values. treated with LTFC compared with 20% (n ÂŒ 8) when Data are shown as meanÂ±SD (mm Hg). patients were treated with the TTFC (P ÂŒ 0.29). In all, 22 (P ÂŒ 0.09). When the pressure reduction from untreated adverse events were detected in the LTFC group and 27 baseline was compared between treatment groups were noted in the TTFC therapy. There were no serious <a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#4">(Table 3), </a>the ï¬ndings mirrored those of the absolute IOP. adverse events recorded in this study. Eye <hr> <A name=5></a>24-h IOP control AGP Konstas et al 5 compared directly, the travoprost-based ï¬xed Baseline 32 TTFC combination provided a lower pressure over the 24 h, a LTFC 30 lower maximum pressure and a lower range of the 28.5  pressure. In addition, following a Bonferroni correction, 28 individual time points at 1000, 1800, and 2000 hours were 26 statistically lower with the TTFC. In contrast, no statistically signiï¬cant difference was observed between 24 groups at the other time points and for the minimum (mm Hg) Â± 95% CI 22 pressure. Mean intraocular pressure 19.6  These ï¬ndings differ from those of Topouzis et al<a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">4 </a>who 20 found, on the ï¬nal efï¬cacy visit, no difference between 18 18.7  the latanoprost and travoprost-based ï¬xed combinations except for the pooled 0900 hours time point when TTFC 06:00 10:00 14:00 18:00 22:00 02:00 24-hrs Time (hours) was better. However, the study design between the earlier trial and our study differed in several ways. Figure 1 The ï¬gure shows the mean IOPÂ±95% conï¬dence The crossover design of the current trial allowed us to interval at each individual time point and for the 24-h pressure for untreated baseline (grey line), travoprost/timolol ï¬xed compare the 24-h IOP characteristics of the two ï¬xed combination (TTFC, solid black line), and latanoprost/timolol combinations in the same eyes. Further, our study carried ï¬xed combination (LTFC, dotted line) treatment groups. out a complete 24-h pressure evaluation, which may allow better separation between two medications. In addition, we dosed the two ï¬xed combinations in the evening. Previous studies have shown that when the Discussion prostaglandin-based ï¬xed combinations were dosed in XFG is a common, sight-threatening form of glaucoma, the evening a greater separation could be observed from which develops as a consequence of an age-related its individual components, or compared with morning malfunction of the extracellular matrix.<a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">18 </a>The worldwide <a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">dosing.5,6,24,25 </a>These 24-h studies have suggested that number of individuals who suffer with XFG or prostaglandin analogues show a peak effect 12 to 24-h exfoliation syndrome is between 60 and 70 million.<a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">18 </a>XFG after <a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#8">dosing.24â26 </a>Consequently, when dosed in the is believed to be a more severe form of glaucoma, with a evening the peak effect of the medicine may occur in the worse long-term prognosis, than primary open-angle following daytime hours when pressures tend at the glaucoma. This is thought to be due to the worse highest by most studies. A retrospective, cross-sectional 24-h pressure characteristics observed in <a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">XFG.19â21</a> study found TTFC to provide signiï¬cantly lower However, the higher level of pressure associated with pressure than latanoprost/timolol maleate ï¬xed XFG may have the advantage of allowing for a greater combination 24-h after instillation.<a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#8">27</a> separation between therapies when performing clinical Finally, our study population consisted of XFG patients trials. In a separate 24-h study, a signiï¬cantly better mean vs primary open-angle glaucoma and ocular 24-h pressure with travoprost (0.6 mm Hg) vs latanoprost hypertension patients in the Topouzis trial.<a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">4 </a>As stated was noted in XFG primarily because of improved efï¬cacy previously, previous research has shown that XFG in the late afternoon and evening with travoprost.<a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#8">22</a> patients typically show higher pressures than those with However, a separate trial by Parmaksiz et al<a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#8">23 </a>did not ï¬nd primary open-angle glaucoma.<a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">9,10 </a>This may have allowed a difference in pressure reduction in XFG patients in a for a greater reduction in pressure and a greater potential three-point diurnal curve. Nonetheless, published to differentiate any differences between these two ï¬xed evidence suggests that because of the higher 24-h combination preparations. Other factors potentially pressure curve characteristics, evaluating patients with related to the greater efï¬cacy of the TTFC in our study XFG might help elucidate if a difference exists in ocular remain unknown and highly speculative. Travoprost is hypotensive efï¬cacy between two glaucoma known to bind to the receptor more strongly that does preparations. latanopro<a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#8">st.28 </a>This might allow for more prolonged The purpose of this study was to evaluate the 24-h IOP contact with the prostanoid receptor and might have efï¬cacy between evening-dosed TTFC and LTFC provided the greater efï¬cacy especially at the end of the speciï¬cally in XFG patients. dosing cycle at 1800 hours as observed in this trial and in This crossover study showed that both the TTFCs and a previous study by Konstas et al.<a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#8">22</a> the LTFCs reduced the IOP from untreated baseline over What does the approximately 1 mm Hg diurnal mean the 24-h pressure curve and for each individual time clinically? Since short-term IOPs are an excepted marker points. However, when these ï¬xed combinations were for long-term clinical outcomes in glaucoma one has to Eye <hr> <A name=6></a>24-h IOP control AGP Konstas et al 6 Table 4 Adverse events recorded in the study Adverse eventra LTFC TTFC P-value Yes No Total Conjunctival hyperemia Yes 2 2 4 (10) 0.29 No 6 30 36 (90) Total 8 (20) 32 (80) 40 (100) Stinging Yes 3 3 6 (15) 0.62 No 1 33 34 (85) Total 4 (10) 36 (90) 40 (100) Hypertrichosis Yes 3 0 3 (7) 0.25 No 3 34 37 (93) Total 6 (15) 34 (85) 40 (100) Skin pigmentation Yes 0 0 0 (0) 0.25 No 3 37 40 (100) Total 3 (7) 37 (93) 40 (100) Itchiness Yes 0 3 3 (7) 0.25 No 0 37 37 (93) Total 0 (0) 40 (100) 40 (100) Watering Yes 1 0 1 (2) 1 No 1 38 39 (98) Total 2 (5) 38 (95) 40 (100) Superï¬cial punctuate keratitis Yes 1 1 2 (5) 1 No 0 38 38 (95) Total 1 (2) 39 (98) 40 (100) Dry eye sensation Yes 0 1 1 (2) 1 No 2 37 39 (98) Total 2 (5) 38 (95) 40 (100) Eyelid swelling Yes 1 1 2 (5) 1 No 0 38 38 (95) Total 1 (2) 39 (98) 40 (100) Abbreviations: LTFC, latanoprost/timolol ï¬xed combination; TTFC, travoprost/timolol ï¬xed combination. aSome patients experienced multiple adverse events. Data are shown as number of patients (%). project long-term results. Several studies have noted that This study suggests that evening-dosed TTFC 1 mm Hg differences over 5 years can alter the incidence may provide greater mean 24-h IOP reduction, of progression in primary open-angle and exfoliation primarily at the 1800 hours time point, than the LTFC patients.<a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#8">29â33 </a>The Early Manifest Glaucoma Trial (EMGT) in XFG. showed speciï¬cally for every 1 mm Hg increase in This study did not evaluate the long-term 24-h efï¬cacy pressure there was a 12â13% increased likelihood of of the TTFC compared with LTFC in primary open-angle progression over 5 <a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#8">years.34</a> glaucoma or for the long-term visual outcomes between However, in exfoliation, pressures are even higher and the two preparations. In addition, we did not evaluate progression more frequent even at normalized directly morning dosing of these two ï¬xed combinations. pressures.<a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#8">33 </a>Just recently, further data from the EMGT Further research is needed to more completely elucidate showed that pressures in exfoliation tend to rise over the efï¬cacy of the TTFC and LTFCs compared with other time (1 mm Hg per year) as opposed to primary open- ï¬xed and unï¬xed therapies. This study was also limited angle glaucoma, which remained <a href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#8">stable.35 </a>Consequently, by the crossover design which has threatens a carryover in exfoliation a 1 mm Hg decrease in pressure may be effect of the medicine between treatment periods. even more important than in primary open-angle Although this effect was not observed statistically an glaucoma. However, prospective long-term studies are inï¬uence from the ï¬rst period medicines can never be needed to conï¬rm this speculation. completely rule-out. In addition because of the small Eye <hr> <A name=7></a>24-h IOP control AGP Konstas et al 7 samples size, an evaluation of safety could not be monotherapy: one-year randomized trial. Arch Ophthalmol made as extensive as in a parallel design. 2002; 120: 915â922. 4 Topouzis F, Melamed S, Danesh-Meyer H, Wells AP, Kozobolis V, Wieland H et al. A 1-year study to compare the Summary efï¬cacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in What was known before K patients with open-angle glaucoma or ocular hypertension. Published evidence suggests that because of the higher Eur J Ophthalmol 2007; 17: 183â190. 24-h pressure curve characteristics associated with 5 Konstas AG, Tsironi S, Vakalis AN, Nasr MB, Stewart JA, exfoliative glaucoma, further evaluating these patients might help elucidate if a difference exists in ocular Nelson LA et al Intraocular pressure control over 24-h using hypotensive efï¬cacy between two glaucoma preparations. travoprost and timolol ï¬xed combination, administered in the morning or evening in primary open-angle and What this study adds exfoliative glaucoma. Acta Ophthalmol 2009; 87: 71â76. K This study suggests that evening dosed travoprost/ 6 Konstas AG, Boboridis K, Tzetzi D, Kallinderis K, Jenkins timolol ï¬xed combination may provide greater mean 24-h JN, Stewart WC. Twenty-four-hour control with intraocular pressure reduction, primarily at the 1800 latanoprost-timolol-ï¬xed combination therapy vs hours time point, than the latanoprost/timolol ï¬xed latanoprost therapy. Arch Ophthalmol 2005; 123: 898â902. combination in exfoliative glaucoma. 7 Konstas AG, Mikropoulos D, Haidich AB, Ntampos KS, Stewart WC. Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate ï¬xed combination Conï¬ict of interest compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. Br J Ophthalmol Dr Stewart receives research funding from Alcon and has 2009; 93: 481â485. been a consultant, but does not receive honoraria or 8 Konstas AG, Mikropoulos D, Stewart WC. Fixed combination therapy in glaucoma. In: Shaarawy TM, perform lectures, and received no support for this Sherwood MB, Hitchings RA, Crowston JG (eds). Glaucoma. particular study. Professor Konstas receives research Medical Diagnosis and Therapy. WB Saunders: Philadelphia, funding and lectures for Alcon. Drs Mikropoulos, 2009; 565â575. Embeslidis, Dimopoulos, and Papanastasiou as well as 9 Konstas AG, Mantziris DA, Stewart WC. Diurnal Professor Haidich do not have conï¬ict of interest to intraocular pressure in untreated exfoliation and primary disclose. open-angle glaucoma. Arch Ophthalmol 1997; 115: 182â185. 10 Konstas AG, Mantziris DA, Cate EA, Stewart WC. Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma. Arch Ophthalmol 1997; Acknowledgements 115: 975â979. 11 Stewart WC, Holmes KT, Johnson MA. Washout periods for The clinical/data collection site (AGP, Greece) and the brimonidine 0.2% and latanoprost 0.005%. Am J Ophthalmol administrative site (WCS, PRN Pharmaceutical Research 2001; 131: 798â799. 12 Book SA. Essentials of Statistics. McGraw Hill: New York, Network, LLC) were solely responsible for design and 1987; pp 205â215. development of the protocol as well as analysis and 13 Simes RJ. An improved Bonferroni procedure for multiple interpretation of data. Alcon was not involved in the tests of signiï¬cance. Biometrika 1986; 73: 751â754. protocol design, development, analysis, or editing 14 Dupont WD, Plummer WD. PS power and sample size process. The clinical/data collection site approached program available for free on the Internet. Controlled Clin Alcon Laboratories, Inc. after the protocol was developed Trials 1997; 18: 274. 15 Duff GR. A double-masked crossover study comparing the and received an unrestricted grant. The administrative effects of carteolol 1 and 2% on intraocular pressure. site did not request or receive ï¬nancial support for this Acta Ophthalmologica 1987; 65: 618â621. study. 16 Miller RG. Beyond ANOVA: Basics of Applied Statistics. Chapman & Hall/CRC: London, 1998; pp 74â76. 17 Siegel S. Nonparametric Statistics for the Behavioral Sciences. References McGraw Hill: New York, 1956; pp 63â67. 18 Konstas AG, Tsironi S, Ritch R. Current concepts in the 1 Barnebey HS, Orengo-Nania S, Flowers BE, Samples J, pathogenesis and management of exfoliation syndrome Mallick S, Landry TA et al. The safety and efï¬cacy of and exfoliative glaucoma. Compr Ophthalmol Update 2006; latanoprost/timolol ï¬xed combination 0.004%/timolol 0.5% 7: 131â141. ï¬xed combination ophthalmic solution. Am J Ophthalmol 19 Konstas AG, Tsironi S, Kozobolis VP. Medical therapy of 2005; 140: 1â7. exfoliative glaucoma. In: Hollo G, Konstas AG (eds). ââFrom 2 Pfeiffer N. A comparison of the ï¬xed combination of Exfoliation Syndrome to Exfoliative Glaucomaââ EGS Book. latanoprost and timolol with its individual components. Dogma: Savona, 2008; pp 135â146. Graefes Arch Clin Exp Ophthalmol 2002; 240: 893â899. 20 Ritch R, Konstas AG, Schloetzer-Schrehardt U. Exfoliation 3 Higginbotham EJ, Feldman R, Stiles M, Dubiner H. syndrome and exfoliative glaucoma. In: Shaarawy TM, Latanoprost and timolol combination therapy vs Sherwood MB, Hitchings RA, Crowston JG (eds). Glaucoma. Eye <hr> <A name=8></a>24-h IOP control AGP Konstas et al 8 Medical Diagnosis and Therapy. WB Saunders: Philadelphia, 28 Sharif NA, Kelly CR, Crider JY, Williams GW, Xu 2009; pp 339â347. SX. Ocular hypotensive FP prostaglandin (PG) analogs: PG 21 Konstas AG, Hollo G, Ritch R. Exfoliative glaucoma. In: receptor subtype binding afï¬nities and selectivities, and Schacknow PN, Samples JR (eds). The Glaucoma Book. A agonist potencies at FP and other PG receptors in Practical, Evidence-Based Approach to Patient Care. Springer: cultured cells. J Ocul Pharmacol Ther 2003; 19: 501â515. New York, 2010. 29 Stewart WC, Konstas AG, Nelson LA, Kruft B. Meta- 22 Konstas AG, Kozobolis VP, Katsimpris IE, Boboridis K, analysis of 24-h intraocular pressure studies evaluating the Koukoula S, Jenkins JN et al. Efï¬cacy and safety of efï¬cacy of glaucoma medicines. Ophthalmology 2008; 115: latanoprost versus travoprost in exfoliative glaucoma 1117â1122. patients. Ophthalmology 2007; 114: 653â657. 30 Stewart WC, Kolker AE, Sharpe ED, Day DG, Holmes KT, 23 Parmaksiz S, YuÂšksel N, Karabas VL, Ozkan B, Demirci G, Leech JN et al. Factors associated with long-term Caglar Y. A comparison of travoprost, latanoprost, and the progression or stability in primary open-angle glaucoma. ï¬xed combination of dorzolamide and timolol in patients Am J Ophthalmol 2000; 130: 274â279. with pseudoexfoliation glaucoma. Eur J Ophthalmol 2006; 16: 31 Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors 73â80. associated with visual loss in patients with advanced 24 Konstas AG, Hollo G, Tsironi S, Durukan I, Goldenfeld M, glaucomatous changes in the optic nerve head. Am J Melamed S. Diurnal intraocular pressure control with Ophthalmol 1993; 116: 176â181. bimatoprost vs latanoprost in exfoliative glaucoma: a 32 Mao LK, Stewart WC, Shields MB. Correlation between crossover observer-masked 3-center study. Br J Ophthalmol intra-ocular pressure control and progressive glaucomatous 2007; 91: 757â760. damage in primary open-angle glaucoma. Am J Ophthalmol 25 Konstas AG, Maltezos AC, Gandi S, Hudgins AC, 1991; 111: 51â55. Stewart WC. Comparison of 24-h intraocular pressure 33 Konstas AG, Hollo G, Astakhov YS, Teus MA, Akopov EL, reduction with two dosing regimens of latanoprost and Leech JN, Stewart WC. Factors associated with long-term timolol maleate in patients with primary open-angle progression or stability in exfoliation glaucoma. glaucoma. Am J Ophthalmol 1999; 128: 15â20. Arch Ophthalmol 2004; 122: 29â33. 26 Konstas AG, Nakos E, Tersis I, Lallos NA, Leech JN, Stewart 34 Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z WC. A comparison of once-daily morning vs evening et al EMGT Group. Predictors of long-term progression in dosing of concomitant latanoprost/timolol. Am J Ophthalmol the early manifest glaucoma trial. Ophthalmology 2007; 114: 2002; 133: 753â757. 1965â1972. 27 Tabet R, Stewart WC, Feldman R, Konstas AG. 35 Hyman L, Heijl A, Leske MC, Bengtsson B, Yang Z, Early A review of additivity to prostaglandin analogs: ï¬xed Manifest Glaucoma Trial Group. Natural history of and unï¬xed combinations. Surv Ophthalmol 2008; 53: intraocular pressure in the early manifest glaucoma trial: a S85âS92. 6-year follow-up. Arch Ophthalmol 2010; 128: 601â607. Eye <hr> <A name="outline"></a><h1>Document Outline</h1> <ul><li><A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#1">24-h Intraocular pressure control with evening-dosed travoprostsoltimolol, compared with latanoprostsoltimolol, fixed combinations in exfoliative glaucoma</A> <ul><li><A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#1">Introduction</A> <li><A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#2">Materials and methods</A> <ul><li><A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#2">Patients</A> <li><A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#2">Methods</A> <li><A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#3">Statistics</A> </ul><li><A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#3">Results</A> <ul><li><A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#3">Patients</A> <li><A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#3">Intraocular pressure</A> <li><A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#4">Adverse events</A> </ul><li><A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#4">Table 1 Overall baseline characteristics and comparison between treatments</A> <li><A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#4">Table 2 Absolute intraocular pressure levels (P-values are adjusted for the Bonferroni correction so any value lt0.05 is statistically significant)</A> <li><A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#4">Table 3 Intraocular pressure reduction from baseline</A> <li><A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#5">Discussion</A> <li><A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#5">Figure 1 The figure shows the mean IOP±95percnt confidence interval at each individual time point and for the 24-h pressure for untreated baseline (grey line), travoprostsoltimolol fixed combination (TTFC, solid black line), and latanoprostsoltimolol fixe</A> <li><A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#6">Table 4 Adverse events recorded in the study</A> <li><A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">Conflict of interest</A> <li><A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">Acknowledgements</A> <li><A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7">References</A> </ul></ul><hr> </BODY> </HTML>

2.ind.html

Κώδικας: Επιλογή όλων: <!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN"><HTML> <HEAD> <TITLE></TITLE> </HEAD> <BODY> <A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#outline" target="contents">Outline</a> <A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#1" target="contents" >Page 1</a> <A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#2" target="contents" >Page 2</a> <A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#3" target="contents" >Page 3</a> <A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#4" target="contents" >Page 4</a> <A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#5" target="contents" >Page 5</a> <A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#6" target="contents" >Page 6</a> <A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#7" target="contents" >Page 7</a> <A href="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html#8" target="contents" >Page 8</a> </BODY> </HTML>

3.

Κώδικας: Επιλογή όλων: <!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Frameset//EN" "http://www.w3.org/TR/html4/frameset.dtd"> <HTML> <HEAD> <TITLE>24-h Intraocular pressure control with evening-dosed travoprost/timolol, compared with latanoprost/timolol, fixed combinations in exfoliative glaucoma</TITLE> <META http-equiv="Content-Type" content="text/html; charset=UTF-8"> <META name="generator" content="pdftohtml 0.36"> <META name="author" content="A G P Konstas"> <META name="date" content="2010-07-15T21:29:15+00:00"> <META name="subject" content="Eye, (2010). doi:10.1038/eye.2010.100"> </HEAD> <FRAMESET cols="100,*"> <FRAME name="links" src="Eye 10 DuoTrav vs Xalacom 24-hr XFG_ind.html"> <FRAME name="contents" src="Eye 10 DuoTrav vs Xalacom 24-hr XFGs.html"> </FRAMESET> </HTML>

Εγκατέστησα το pdfedit καί το πρόβλημα φαίνεται νά είναι περισσότερο σύνθετο

Κώδικας: Επιλογή όλων: Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIOC+AdvPalB' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIPI+AdvPalR' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' Error: Couldn't create a font for 'IODIOB+AdvFrutiger-L' thanasis@thanasis-VGN-CS11S-Q ~ $

τμήματικά κάνοντας copy-paste τίς προβληματικές περιοχές από το acroread στό ΟΟ text editor ή στο gpdftext αυτές διαβάζονται κανονικά
όμως δυστυχώς σε copy-paste ολόκληρου τού άρθρου παρόλο πού δέν υπάρχει πρόβλημα γραμματοσειράς, χάνεται η δομή του (πίνακες, παραπομπές)

Βρήκα κάτι γιά frutiger fonts free download for linux αλλά διατηρώ επιφυλάξεις γιά να τά κατεβάσω γιατί δέν τά βρίσκω στά επίσημα αποθετήρια

από **MakisM1** » 03 Δεκ 2010, 16:22

Εχεις ΡΜ

Ιστοσελίδα · από **Th P** » 04 Δεκ 2010, 17:18

update
ανέβασα το θέμα στό forum τής adobe
άν υπάρξει εξέλιξη θα ενημερώσω

Φιλικά
Θανάσης Π.

από **MakisM1** » 04 Δεκ 2010, 17:21

Να βρεις τζαμπα τους Frutiger ειναι κομματι δυσκολο, αλλα φαινεται οτι καποιοες εταιρειες τους εχουν υιοθετησει!

πρόβλημα με γραμματοσειρά σέ pdf

πρόβλημα με γραμματοσειρά σέ pdf

Re: πρόβλημα με γραμματοσειρά σέ pdf

Re: πρόβλημα με γραμματοσειρά σέ pdf

Re: πρόβλημα με γραμματοσειρά σέ pdf

Re: πρόβλημα με γραμματοσειρά σέ pdf

Re: πρόβλημα με γραμματοσειρά σέ pdf

Re: πρόβλημα με γραμματοσειρά σέ pdf

Re: πρόβλημα με γραμματοσειρά σέ pdf

Re: πρόβλημα με γραμματοσειρά σέ pdf

Re: πρόβλημα με γραμματοσειρά σέ pdf